Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.
With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...
Pharmaceutical Technology on MSN7h
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drugNovo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...
As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is ...
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
Through Synapticure, patients will be able to use LillyDirect to find in-person Alzheimer’s specialists or to connect with ...
Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly ...
INDIANAPOLIS: Drugmaker Eli Lilly and Company’s SVP and chief communications officer, Kathryn Beiser, has resigned. Beiser ...
Almost all the biotechs (94%) are expecting their manufacturing costs to rise sharply if tariffs are placed on imports from the EU, while 50% of them said they would need to find new outsourcing ...
Digging deeper into the BIO survey results, 94% of companies polled said they expect tariffs on the EU to drive up ...
Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback